Effect of Adjuvant Chemo on Elderly Patients’ Quality of Life

Article

In this Medical News Minute developed exclusively for Cancer Network, Dr. Bobby Lazzara discusses recently published research that looks at quality of life outcome measures for elderly breast cancer patients who receive adjuvant chemotherapy.

In this Medical News Minute developed exclusively for Cancer Network, Dr. Bobby Lazzara discusses recently published research that looks at quality of life outcome measures for elderly breast cancer patients who receive adjuvant chemotherapy.

Recent Videos
Endobronchial ultrasound, robotic bronchoscopy, or other expensive procedures may exacerbate financial toxicity for patients seeking lung cancer care.
Destigmatizing cancer care for incarcerated patients may help ensure that they feel supported both in their treatment and their humanity.
Patients with mediastinal lymph node involved-lung cancer may benefit from chemoimmunotherapy in the neoadjuvant setting.
2 experts are featured in this series.
Advancements in antibody drug conjugates, bispecific therapies, and other targeted agents may hold promise in lung cancer management.
A lower percentage of patients who were released within 1 year of incarceration received guideline-concurrent care vs incarcerated patients.
Stressing the importance of prompt AE disclosure before they become severe can ensure that a patient can still undergo resection with curative intent.
A collaboration between the Connecticut Departments of Health and Corrections and the COPPER Center aimed to improve outcomes among incarcerated patients.
Thomas Marron, MD, PhD, presented a session on clinical data that established standards of care for stage II and III lung cancer treatment at CFS 2025.
Related Content
Fertility-sparing surgery showed comparable efficacy vs hysterectomy in early-stage cervical cancer, with a 5-year RFS rate of 92% vs 96.4%, respectively.

Fertility-Sparing Surgery May Be Safe Despite Recurrence in Cervical Cancer

Tim Cortese
November 21st 2025
Article

Fertility-sparing surgery showed comparable efficacy vs hysterectomy in early-stage cervical cancer, with a 5-year RFS rate of 92% vs 96.4%, respectively.

Michael Barish, PhD, discusses a novel cellular therapy for patients with glioblastoma that harnesses chlorotoxin, a peptide found in scorpion venom.

How Can Chlorotoxin-Directed CAR T-Cell Therapy Impact Glioblastoma Care?

Michael Barish, PhD
November 17th 2025
Podcast

Michael Barish, PhD, discusses a novel cellular therapy for patients with glioblastoma that harnesses chlorotoxin, a peptide found in scorpion venom.

Results from the KEYNOTE-905 trial led to the approval of pembrolizumab/enfortumab vedotin in muscle invasive bladder cancer.

FDA OKs Pembrolizumab/Enfortumab Vedotin in Muscle Invasive Bladder Cancer

Ariana Pelosci
November 21st 2025
Article

Results from the KEYNOTE-905 trial led to the approval of pembrolizumab/enfortumab vedotin in muscle invasive bladder cancer.

Experts discussed supportive care and why it should be integrated into standard oncology care.

How Supportive Care Methods Can Improve Oncology Outcomes

Declan Walsh, MD;Denise B. Reynolds, RD;Adam Friedman, MD, FAAD;Daniel C. McFarland, DO;Michelle Fingeret, PhD;Christian J. Nelson, PhD;William S. Breitbart, MD
November 10th 2025
Podcast

Experts discussed supportive care and why it should be integrated into standard oncology care.

Results from the C-POST trial showed that cemiplimab improved DFS vs placebo in patients with CSCC at high risk of recurrence following surgery and radiation.

EC Approves Adjuvant Cemiplimab in CSCC at High Risk of Recurrence

Tim Cortese
November 20th 2025
Article

Results from the C-POST trial showed that cemiplimab improved DFS vs placebo in patients with CSCC at high risk of recurrence following surgery and radiation.

Zidesamtinib elicited positive activity in patients with advanced ROS1-positive NSCLC who previously received a ROS1 TKI in the phase 1/2 ARROS-1 trial.

FDA Accepts NDA for Zidesamtinib in Pretreated Advanced ROS1+ NSCLC

Tim Cortese
November 20th 2025
Article

Zidesamtinib elicited positive activity in patients with advanced ROS1-positive NSCLC who previously received a ROS1 TKI in the phase 1/2 ARROS-1 trial.